Key result
Arachidonic acid at 1.6 mM reproducibly induced platelet aggregation in 26 healthy volunteers without overcoming the antiplatelet effect of 6 daily doses of aspirin.
Why the study?
What concentration of arachidonic acid reliably induces ex vivo platelet aggregation without overcoming the inhibitory effect of low-dose aspirin?
What concentration of arachidonic acid reliably induces ex vivo platelet aggregation without overcoming the inhibitory effect of low-dose aspirin?
A concentration of 1.6 mM arachidonic acid is optimal for ex vivo platelet aggregation testing, as it reliably induces aggregation without overriding the effects of low-dose aspirin.
Answers are grounded in this paper and cite their sources.
1.6 mM arachidonic acid may aid ex vivo aspirin monitoring; hypothesis-generating and requires validation in patients.
Inhibition of ex vivo arachidonic acid (AA)-induced aggregation is a biomarker for the isotype selectivity of cyclooxygenase (COX) inhibitors since platelets express COX-1 but not COX-2. At low concentrations, there is broad inter- and intrasubject variability in AA-induced aggregation of platelets ex vivo. This study defined a concentration that reliably induces aggregation without overcoming inhibition by therapeutic aspirin therapy (ASA, 81-mg) treatment. Logistic regression analysis of ex vivo aggregation, induced with increasing concentrations of AA in platelet-rich plasma (PRP), estimated that platelets from > or = 90% of subjects would aggregate at > or = 1.5 mM AA (95% confidence interval [CI], 1.1, 2.1). A concentration of 1.6 mM AA failed to aggregate platelets from 26 healthy volunteers, who had previously aggregated at this concentration, following six daily oral doses of 81 mg of ASA. These data demonstrate that 1.6 mM AA reproducibly induces platelet aggregation in PRP from healthy volunteers without overcoming the antiplatelet effect of daily low-dose aspirin therapy.
No takes yet. Share an insight, caveat, or question.
Burke et al. (2003) studied Healthy volunteers (n=26). Arachidonic acid and Aspirin was evaluated on Arachidonic acid concentration estimated to aggregate platelets from ≥90% of subjects (1.5 mM, 95% CI 1.1-2.1). Arachidonic acid at 1.6 mM reproducibly induced platelet aggregation in 26 healthy volunteers without overcoming the antiplatelet effect of 6 daily doses of aspirin.
Synapse has enriched 10 related papers. Consider them for comparative context: